THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES

Header Logo

Grant Skrepnek

Concepts (368)

Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.


Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Hospitalization
8
2021
202
2.710
Why?
Antipsychotic Agents
3
2022
24
2.330
Why?
Emergency Service, Hospital
7
2020
122
2.220
Why?
Medicaid
8
2022
54
2.080
Why?
United States
37
2022
2149
2.050
Why?
Diabetic Foot
4
2017
17
1.940
Why?
Hepatitis C, Chronic
4
2019
32
1.870
Why?
Cost of Illness
6
2018
54
1.660
Why?
Schizophrenia
2
2022
47
1.530
Why?
Pericarditis
2
2021
14
1.390
Why?
Medication Therapy Management
3
2019
18
1.380
Why?
Cross-Sectional Studies
18
2022
968
1.380
Why?
Health Care Costs
7
2015
51
1.360
Why?
Antiviral Agents
3
2019
112
1.220
Why?
Hepacivirus
2
2019
48
1.220
Why?
Drug Interactions
9
2019
78
1.170
Why?
Retrospective Studies
27
2022
2557
1.110
Why?
Humans
66
2025
28121
1.080
Why?
Cost-Benefit Analysis
8
2014
112
0.980
Why?
Hospital Charges
3
2015
7
0.980
Why?
Neoplasms
4
2018
818
0.950
Why?
Personnel Staffing and Scheduling
2
2025
41
0.930
Why?
Middle Aged
27
2019
7164
0.920
Why?
Male
42
2019
13487
0.920
Why?
Ambulatory Care
4
2022
60
0.880
Why?
Diabetes Mellitus
2
2018
215
0.870
Why?
Inpatients
5
2018
56
0.850
Why?
Female
40
2019
15156
0.840
Why?
Delivery of Health Care
3
2017
118
0.820
Why?
Psychotic Disorders
1
2022
22
0.800
Why?
Pulmonary Disease, Chronic Obstructive
3
2012
62
0.790
Why?
Bipolar Disorder
1
2022
41
0.780
Why?
Drug Costs
3
2018
17
0.770
Why?
Length of Stay
8
2021
232
0.750
Why?
Adult
21
2022
7757
0.720
Why?
Cohort Studies
9
2021
886
0.720
Why?
Multivariate Analysis
9
2018
300
0.710
Why?
Aged
17
2022
5416
0.690
Why?
Anti-Bacterial Agents
6
2018
523
0.680
Why?
Alzheimer Disease
1
2022
218
0.660
Why?
Nursing Staff, Hospital
1
2020
19
0.650
Why?
Depression
2
2014
215
0.650
Why?
Virus Diseases
1
2020
39
0.650
Why?
HIV Infections
2
2018
157
0.640
Why?
Coinfection
1
2018
14
0.610
Why?
Acquired Immunodeficiency Syndrome
1
2018
22
0.610
Why?
Comorbidity
7
2019
256
0.610
Why?
Financial Statements
1
2018
2
0.600
Why?
Hepatitis C
1
2018
40
0.600
Why?
Medication Adherence
2
2018
47
0.600
Why?
Managed Care Programs
6
2015
16
0.590
Why?
Patient Care Management
1
2018
10
0.590
Why?
Education, Pharmacy, Graduate
1
2018
18
0.590
Why?
Lung Diseases
1
2018
43
0.570
Why?
Liver Cirrhosis
1
2018
72
0.570
Why?
Health Expenditures
3
2014
30
0.540
Why?
Administration, Oral
4
2022
189
0.500
Why?
Poisoning
1
2015
2
0.500
Why?
Health Status
2
2014
148
0.490
Why?
Acetaminophen
1
2015
11
0.490
Why?
Asthma
3
2008
60
0.490
Why?
Quality-Adjusted Life Years
3
2014
18
0.490
Why?
Healthcare Disparities
2
2019
92
0.480
Why?
Oklahoma
5
2025
1005
0.480
Why?
Hypertension
1
2018
309
0.480
Why?
Medication Errors
4
2009
26
0.460
Why?
Sepsis
1
2015
84
0.450
Why?
Community Pharmacy Services
3
2018
22
0.450
Why?
Regression Analysis
5
2012
210
0.450
Why?
Life Expectancy
1
2014
23
0.450
Why?
Patient Outcome Assessment
1
2014
14
0.450
Why?
Sertraline
3
2008
5
0.440
Why?
Treatment Outcome
11
2018
2380
0.440
Why?
Vancomycin
3
2018
58
0.440
Why?
Serotonin Uptake Inhibitors
3
2008
26
0.430
Why?
Vascular Surgical Procedures
1
2014
54
0.430
Why?
Efficiency
2
2013
18
0.430
Why?
Aged, 80 and over
8
2019
2021
0.430
Why?
Educational Measurement
3
2025
128
0.420
Why?
Clostridium Infections
3
2018
67
0.420
Why?
Bayes Theorem
2
2019
100
0.420
Why?
Surveys and Questionnaires
4
2014
969
0.420
Why?
Endovascular Procedures
1
2014
70
0.420
Why?
Sick Leave
1
2012
1
0.410
Why?
Leukemia, Lymphocytic, Chronic, B-Cell
1
2013
44
0.410
Why?
Health Care Sector
1
2012
1
0.410
Why?
Practice Patterns, Physicians'
5
2022
163
0.400
Why?
Pharmacists
4
2018
73
0.400
Why?
Hospitals, Veterans
3
2008
22
0.390
Why?
Drug Prescriptions
5
2019
46
0.390
Why?
Curriculum
3
2025
291
0.390
Why?
Commerce
1
2012
54
0.390
Why?
Risk Factors
7
2018
2084
0.380
Why?
Medical Order Entry Systems
2
2009
4
0.380
Why?
Diabetes Mellitus, Type 2
1
2015
330
0.370
Why?
Patient Readmission
2
2022
103
0.370
Why?
Disease Progression
1
2013
473
0.370
Why?
Drug-Related Side Effects and Adverse Reactions
3
2008
67
0.360
Why?
Adolescent
11
2019
3123
0.360
Why?
Students, Pharmacy
2
2025
83
0.350
Why?
Socioeconomic Factors
3
2018
248
0.350
Why?
Diphosphonates
1
2010
15
0.350
Why?
Bone Density Conservation Agents
1
2010
18
0.350
Why?
Treatment Failure
3
2019
69
0.350
Why?
Economics, Pharmaceutical
2
2008
6
0.350
Why?
Decision Support Techniques
4
2013
50
0.350
Why?
Antineoplastic Combined Chemotherapy Protocols
1
2014
411
0.340
Why?
Pharmacy Service, Hospital
3
2008
14
0.340
Why?
Osteoporosis
1
2010
63
0.340
Why?
Health Care Surveys
5
2017
66
0.320
Why?
Adrenal Cortex Hormones
3
2020
75
0.320
Why?
Sustained Virologic Response
2
2019
4
0.320
Why?
Workload
2
2007
38
0.310
Why?
Drug Information Services
1
2009
1
0.310
Why?
Fentanyl
2
2019
34
0.290
Why?
Child
9
2019
2242
0.290
Why?
Child, Preschool
6
2019
1137
0.290
Why?
Longitudinal Studies
3
2018
413
0.280
Why?
Analgesics, Opioid
2
2019
113
0.280
Why?
Critical Illness
2
2017
68
0.270
Why?
Young Adult
5
2018
2731
0.260
Why?
Medicare
2
2018
121
0.260
Why?
Mortality
2
2018
46
0.260
Why?
Telecommunications
1
2006
4
0.260
Why?
Hospital Mortality
2
2018
149
0.250
Why?
Linear Models
3
2015
203
0.250
Why?
Levofloxacin
1
2005
3
0.240
Why?
Ofloxacin
1
2005
4
0.240
Why?
Clarithromycin
1
2005
7
0.240
Why?
Erythromycin
1
2005
15
0.240
Why?
Chronic Disease
3
2017
273
0.240
Why?
Azithromycin
1
2005
11
0.240
Why?
Pneumonia, Bacterial
1
2005
18
0.230
Why?
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
2005
17
0.230
Why?
Community-Acquired Infections
1
2005
31
0.230
Why?
Acute Disease
3
2020
158
0.230
Why?
Bone Marrow Transplantation
1
2005
49
0.230
Why?
Amputation
2
2015
42
0.230
Why?
Piperazines
1
2005
48
0.230
Why?
Antineoplastic Agents
3
2010
678
0.220
Why?
Accounting
1
2004
1
0.220
Why?
Drug Utilization
2
2022
28
0.220
Why?
Pyrimidines
1
2005
126
0.220
Why?
Drug Industry
1
2004
14
0.220
Why?
Education, Pharmacy
2
2025
116
0.220
Why?
Hospital Costs
2
2014
29
0.210
Why?
Paliperidone Palmitate
1
2022
3
0.200
Why?
Heart Failure
1
2005
247
0.200
Why?
Obesity
2
2019
668
0.200
Why?
Drug Therapy, Combination
4
2018
207
0.200
Why?
Injections
1
2022
31
0.200
Why?
Delayed-Action Preparations
1
2022
43
0.200
Why?
Outpatients
1
2022
44
0.200
Why?
Hospitals
1
2022
81
0.190
Why?
Multiple Sclerosis
2
2013
87
0.190
Why?
Patient Discharge
1
2022
103
0.190
Why?
Pericardiectomy
1
2021
3
0.190
Why?
Pericardiocentesis
1
2021
4
0.190
Why?
Anti-Inflammatory Agents, Non-Steroidal
2
2020
77
0.170
Why?
Infant
4
2018
996
0.170
Why?
Pharmacies
2
2012
19
0.170
Why?
Databases as Topic
3
2010
22
0.160
Why?
Chest Pain
1
2020
26
0.160
Why?
Triage
1
2020
33
0.160
Why?
Anesthetics, Intravenous
2
2017
15
0.160
Why?
United States Department of Veterans Affairs
3
2008
26
0.160
Why?
Infant, Newborn
3
2019
873
0.160
Why?
Neonatal Abstinence Syndrome
1
2019
10
0.150
Why?
Diagnosis-Related Groups
1
2018
10
0.150
Why?
Time Factors
3
2017
1593
0.150
Why?
Methadone
1
2019
17
0.150
Why?
Postoperative Complications
2
2014
613
0.150
Why?
Occupations
1
2018
9
0.150
Why?
Aspirin
1
2020
124
0.150
Why?
Genotype
2
2018
457
0.150
Why?
Administrative Claims, Healthcare
1
2018
2
0.150
Why?
Prescription Drug Misuse
1
2018
5
0.150
Why?
Writing
1
2018
14
0.150
Why?
Feedback
1
2018
33
0.150
Why?
Sleep Apnea Syndromes
1
2018
31
0.150
Why?
Coronary Disease
1
2019
119
0.150
Why?
Drug Overdose
1
2018
11
0.150
Why?
Diagnosis, Differential
1
2020
372
0.150
Why?
Prescription Drugs
1
2018
15
0.150
Why?
Retirement
1
2018
11
0.150
Why?
Needs Assessment
1
2018
55
0.150
Why?
Education
1
2018
33
0.150
Why?
Acute Coronary Syndrome
1
2019
64
0.150
Why?
Follow-Up Studies
2
2018
1014
0.140
Why?
Tobramycin
1
2017
13
0.140
Why?
Opioid-Related Disorders
1
2018
41
0.140
Why?
Metronidazole
1
2017
16
0.140
Why?
Pharmaceutical Services
1
2018
41
0.140
Why?
Learning
1
2018
97
0.140
Why?
Patient Compliance
2
2008
75
0.140
Why?
Logistic Models
2
2018
407
0.140
Why?
Heart Defects, Congenital
1
2018
93
0.140
Why?
Citalopram
2
2007
7
0.140
Why?
Hypnotics and Sedatives
1
2017
29
0.140
Why?
Antidepressive Agents
2
2007
29
0.130
Why?
Medical Errors
1
2016
9
0.130
Why?
Odds Ratio
2
2014
237
0.130
Why?
Anti-HIV Agents
1
2016
20
0.130
Why?
Survival Analysis
2
2015
289
0.130
Why?
Depressive Disorder
2
2007
56
0.130
Why?
Patient Transfer
1
2016
43
0.130
Why?
Incidence
2
2015
562
0.130
Why?
State Health Plans
1
2015
3
0.130
Why?
Fee-for-Service Plans
1
2015
8
0.130
Why?
Adjuvants, Immunologic
2
2013
68
0.120
Why?
Skin Diseases, Bacterial
1
2015
9
0.120
Why?
Soft Tissue Infections
1
2015
10
0.120
Why?
Costs and Cost Analysis
3
2015
40
0.120
Why?
Health Knowledge, Attitudes, Practice
2
2008
296
0.120
Why?
Risk
2
2012
136
0.110
Why?
Mediterranean Region
1
2014
2
0.110
Why?
Risk Assessment
4
2019
611
0.110
Why?
Developed Countries
1
2014
7
0.110
Why?
Patient Admission
1
2014
29
0.110
Why?
Limb Salvage
1
2014
21
0.110
Why?
Injections, Intravenous
2
2012
65
0.110
Why?
Developing Countries
1
2014
50
0.110
Why?
Scorpion Venoms
1
2013
2
0.110
Why?
Antivenins
1
2013
9
0.110
Why?
Marketing
1
2013
35
0.110
Why?
Recurrence
3
2018
323
0.100
Why?
Models, Theoretical
1
2014
134
0.100
Why?
Analgesia, Epidural
1
2012
4
0.100
Why?
Deferoxamine
1
2012
3
0.100
Why?
Iron Chelating Agents
1
2012
2
0.100
Why?
Interferon-beta
1
2013
40
0.100
Why?
Triazoles
1
2012
16
0.100
Why?
Benzoates
1
2012
30
0.100
Why?
Pancreaticoduodenectomy
1
2012
42
0.100
Why?
Conscious Sedation
1
2012
10
0.100
Why?
Emergencies
1
2012
28
0.100
Why?
Postoperative Care
1
2012
68
0.100
Why?
Propofol
1
2012
10
0.100
Why?
Ovarian Neoplasms
2
2010
595
0.100
Why?
Anemia, Sickle Cell
1
2012
39
0.100
Why?
Drug Therapy, Computer-Assisted
2
2009
4
0.100
Why?
Data Collection
3
2008
106
0.090
Why?
Monte Carlo Method
3
2008
62
0.090
Why?
Reproducibility of Results
1
2014
773
0.090
Why?
Etidronic Acid
1
2010
1
0.090
Why?
Osteitis
1
2010
2
0.090
Why?
Jaw Diseases
1
2010
4
0.090
Why?
Alendronate
1
2010
6
0.090
Why?
Oral Surgical Procedures
1
2010
6
0.090
Why?
Osteomyelitis
1
2010
14
0.090
Why?
Imidazoles
1
2010
63
0.090
Why?
Multiple Myeloma
1
2010
38
0.090
Why?
Insurance, Health, Reimbursement
2
2013
10
0.090
Why?
Databases, Factual
3
2018
255
0.090
Why?
Quality of Life
1
2014
491
0.080
Why?
Neoplasms, Glandular and Epithelial
1
2010
72
0.080
Why?
Electronic Prescribing
1
2009
2
0.080
Why?
Prevalence
1
2010
494
0.080
Why?
Markov Chains
2
2007
16
0.080
Why?
Outpatient Clinics, Hospital
1
2008
7
0.080
Why?
Medical Oncology
1
2010
94
0.080
Why?
Urokinase-Type Plasminogen Activator
1
2008
11
0.080
Why?
Tissue Plasminogen Activator
1
2008
37
0.070
Why?
Albuterol
1
2008
4
0.070
Why?
Adrenergic beta-Agonists
1
2008
19
0.070
Why?
Bronchodilator Agents
1
2008
15
0.070
Why?
Peripheral Vascular Diseases
1
2008
64
0.070
Why?
Adverse Drug Reaction Reporting Systems
1
2007
13
0.070
Why?
Prostatic Neoplasms
1
2010
277
0.070
Why?
Ribavirin
1
2007
9
0.070
Why?
Interferon-alpha
1
2007
50
0.070
Why?
Program Development
1
2007
77
0.070
Why?
Confidence Intervals
1
2007
68
0.070
Why?
Neoadjuvant Therapy
1
2007
73
0.070
Why?
Antihypertensive Agents
1
2007
56
0.070
Why?
Lung Neoplasms
1
2010
354
0.070
Why?
Health Education
1
2007
71
0.060
Why?
Carcinoma
1
2007
75
0.060
Why?
Polyethylene Glycols
1
2007
100
0.060
Why?
Severity of Illness Index
3
2018
454
0.060
Why?
Program Evaluation
1
2007
167
0.060
Why?
Attitude to Computers
1
2006
7
0.060
Why?
Cisplatin
1
2007
179
0.060
Why?
Urbanization
1
2006
8
0.060
Why?
Automation
1
2006
19
0.060
Why?
Drug Utilization Review
1
2005
7
0.060
Why?
Sodium Potassium Chloride Symporter Inhibitors
1
2005
4
0.060
Why?
Digoxin
1
2005
8
0.060
Why?
Angiotensin-Converting Enzyme Inhibitors
1
2005
32
0.060
Why?
Adrenergic beta-Antagonists
1
2005
66
0.060
Why?
Clinical Competence
1
2007
229
0.060
Why?
Models, Econometric
1
2005
5
0.060
Why?
Breast Neoplasms
1
2010
464
0.060
Why?
Imatinib Mesylate
1
2005
14
0.060
Why?
Benzamides
1
2005
34
0.060
Why?
Dose-Response Relationship, Drug
2
2019
605
0.060
Why?
Biomedical Research
1
2005
97
0.050
Why?
Diarrhea
2
2017
56
0.050
Why?
Practice Guidelines as Topic
1
2004
242
0.050
Why?
Insurance Claim Review
2
2012
11
0.040
Why?
Metabolic Clearance Rate
1
2019
18
0.040
Why?
Proportional Hazards Models
2
2012
226
0.040
Why?
Academic Medical Centers
1
2019
75
0.040
Why?
Propensity Score
1
2018
55
0.040
Why?
Sex Factors
2
2012
465
0.040
Why?
Computer Simulation
1
2019
230
0.040
Why?
Nurse Practitioners
2
2008
8
0.040
Why?
Disease Management
1
2018
88
0.040
Why?
Leukocyte Count
1
2017
25
0.040
Why?
Body Mass Index
1
2019
398
0.040
Why?
Administration, Inhalation
1
2017
35
0.040
Why?
Age Factors
2
2012
733
0.040
Why?
Insurance, Pharmaceutical Services
2
2008
9
0.040
Why?
Drug Monitoring
1
2017
36
0.040
Why?
Cystic Fibrosis
1
2017
32
0.030
Why?
Physicians
2
2008
82
0.030
Why?
Infusions, Intravenous
1
2017
101
0.030
Why?
Acute Kidney Injury
1
2017
74
0.030
Why?
Registries
1
2019
386
0.030
Why?
Hospitals, Teaching
1
2016
26
0.030
Why?
African Americans
1
2019
350
0.030
Why?
Neutrophils
1
2017
181
0.030
Why?
Randomized Controlled Trials as Topic
2
2007
385
0.030
Why?
Drug Administration Schedule
1
2015
223
0.030
Why?
Pregnancy
1
2019
1181
0.030
Why?
Health Services Accessibility
1
2015
101
0.030
Why?
Patient Selection
1
2015
148
0.030
Why?
Interferon beta-1a
1
2013
4
0.030
Why?
Absenteeism
1
2013
7
0.030
Why?
Injections, Intramuscular
1
2013
22
0.030
Why?
Patient Preference
1
2012
31
0.020
Why?
Respiratory Insufficiency
1
2012
14
0.020
Why?
Hypotension
1
2012
19
0.020
Why?
Pain, Postoperative
1
2012
62
0.020
Why?
Kaplan-Meier Estimate
1
2012
194
0.020
Why?
Blood Transfusion
1
2012
77
0.020
Why?
Game Theory
1
2010
1
0.020
Why?
Interviews as Topic
1
2010
156
0.020
Why?
Neoplasm Staging
1
2010
478
0.020
Why?
Physician Assistants
1
2008
14
0.020
Why?
Salmeterol Xinafoate
1
2008
1
0.020
Why?
Arizona
1
2008
38
0.020
Why?
Medical Records Systems, Computerized
1
2008
21
0.020
Why?
Observation
1
2007
5
0.020
Why?
Data Interpretation, Statistical
1
2008
58
0.020
Why?
Models, Economic
1
2007
8
0.020
Why?
Clinical Pharmacy Information Systems
1
2007
5
0.020
Why?
Ambulatory Care Facilities
1
2007
54
0.020
Why?
Infusions, Parenteral
1
2007
37
0.020
Why?
Safety Management
1
2007
14
0.020
Why?
Office Visits
1
2007
8
0.020
Why?
Nausea
1
2007
17
0.020
Why?
Erectile Dysfunction
1
2007
15
0.020
Why?
Thyroid Hormones
1
2007
36
0.020
Why?
Medical Audit
1
2007
15
0.020
Why?
Headache
1
2007
34
0.020
Why?
Pharmaceutical Preparations
1
2007
46
0.020
Why?
Guideline Adherence
1
2007
94
0.020
Why?
Sleep Initiation and Maintenance Disorders
1
2007
24
0.020
Why?
Fibrosis
1
2007
133
0.020
Why?
Attitude of Health Personnel
1
2007
143
0.020
Why?
Recombinant Proteins
1
2007
413
0.020
Why?
Case-Control Studies
1
2008
722
0.020
Why?
Double-Blind Method
1
2007
414
0.020
Why?
Research Design
1
2007
182
0.020
Why?
Anticoagulants
1
2007
294
0.010
Why?
Liver
1
2007
434
0.010
Why?
Algorithms
1
2007
433
0.010
Why?
Skrepnek's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (368)
Explore
_
Co-Authors (12)
Explore
_
Similar People (55)
Explore
_
Same Department Expand Description
Explore
_
Physical Neighbors
_

THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES